Pure Global
NCT06400485

AMT-676 in Patients With Advanced Solid Tumors

First-in-Human, Phase 1 Study of AMT-676 in Patients With Advanced Solid Tumors
Multitude Therapeutics Inc.·Phase 1·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Advanced Solid Tumors
Drug/Device/Intervention
AMT-676
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Multitude Therapeutics Inc.
Location
Randwick,Macquarie,Greenslopes,Melbourne,Nedlands, Australia
Timeline & enrollment
Phase
Phase 1
Start date
May 09, 2024
End date
Feb 14, 2026
Enrollment
24 participants
Primary outcome

Recommended Phase 2 Dose (RP2D),Maximum Tolerated Dose (MTD),Type, incidence and severity of Adverse Events

Summary

This is a first-in-human, non-randomized, open-label, multicenter Phase 1 study will evaluate
 the Maximum tolerated dose (MTD)/the recommended Phase 2 Dose (RP2D), safety, tolerability,
 anti-drug activity, pharmacokinetics, pharmacodynamics and immunogenicity of AMT-676 in
 Patients with Advanced Solid Tumors.

ICD-10 classifications
Malignant neoplasm: PrepuceCarcinoma in situ, unspecifiedMalignant neoplasm: Connective and soft tissue, unspecifiedMalignant neoplasm: ParametriumMalignant neoplasm: Orbit
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06400485
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06400485 through Pure Global AI's free database. This Phase 1 trial is sponsored by Multitude Therapeutics Inc. and is currently Not yet recruiting. The study focuses on Advanced Solid Tumors. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.